Navigating the Evolving Landscape of Medical Affairs with Steve Royle
34 minAudio
Steve Royle is an innovative pharmaceutical professional with experience in both the commercial and medical affairs sides of the industry. After starting in sales and marketing, Steve moved to the agency side of global medical communications and medical education. He went on to found Swipe Health and Rumi. Recently, Steve has used his expertise to create mymedicalafairs.com, a Netflix-style database of medical affairs events and topics. Through mymedicalaffairs.com, we crowdsourc... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00COVID was this massive accelerant for the need to be really good digitally. And that is widely recognized, and the problem is it's so widely recognized that every pharma company on earth is trying to push more and more digital. Hello, hello, and welcome to Pharma Sessions, the podcast where medical affairs professionals talk to each other and hopefully learn how to do their jobs just a little bit better. Today I spoke with Steve Royal.
SPEAKER_00Steve and I actually did something a little different. Steve runs mymedicalaffairs.com amongst his other projects and we crowdsourced the questions for today. We have three great questions for people who are experts in their own right, and I can't wait to get into it. So let's dive right in. Hello, Steve. How are you? Welcome to the States.
SPEAKER_01Hi, John. Thank you. It's wonderful to be here. It's been quite some time actually. Haven't um ventured over since before uh the pandemic. So first trip back, and it's uh just as wonderful as I remember it.
SPEAKER_00Oh, excellent, excellent. So I'm here, of course, with Steve Royal, uh founder of Swipe Health, the Rumi platform, my medical affairs. Anything else, Steve?
SPEAKER_01No, that's uh more than enough to keep me busy along with my uh my two boys under under the age of four. Uh between them all that are uh they keep me pretty um shy of sleep. Good. It's actually good, it helps me manage the jet lag better.
SPEAKER_00Nice, you're used to it.
SPEAKER_01Indeed.
SPEAKER_00Um so do you want to start by telling us how how you got here, how you got to be focused on metapharis?
SPEAKER_01Yeah, certainly. So um my my original entry into the pharmaceutical industry was in the commercial side, and uh I I was uh one of those who carried the bag and uh in sales and made my way into marketing. But then after a while I jumped over to the agency side in global um medical communications and medical education and that type of thing. So I got my first kind of taste there, but it wasn't until I started up Swipe Health I kind of fell back on what I was uh traditionally more comfortable with in a commercial approach, and one of those approaches was um just an interesting type of campaign where we used published and still use published research as a branding element and disseminate it uh to align with with the key messaging of uh of other campaigns.
SPEAKER_01Uh however, because um public published research was involved, this type of campaign has slowly moved over, migrated under the remit of medical affairs. So more and more of my customers are back in the medical affairs space, and of course, we've also got a um an asynchronous advisory board uh meeting platform called Rumi. And uh, whereas once upon a time, certainly in my day, advisory boards were the were the property of uh the commercial teams. Uh in fact, my first uh marketing director said if if you get nothing else right, get your advisory boards right.
SPEAKER_01They're the most important channel for building relationships and um and building towards success in this industry. So, but yeah, now ad boards have most certainly come under the remit of medical affairs. So, with more and more interactions with medical affairs, I found myself feeling a little bit out of my depth. Uh, everybody that I was talking to had a great many more deal uh letters behind their name than what I do. I've got a loan couple. Uh so I thought, well, it's probably about time I tried to upskill myself and learn a little bit more so I could speak a little bit more intelligently to the issues and challenges in the industry.
SPEAKER_01Uh so started doing some research and was overwhelmed by the amount of content online for medical affairs professionals, whether it be courses or conferences, but webinars and podcasts and all types of videos, all types of uh media and formats that was actually difficult to get a grasp of what I should be uh watching and uh where I would find it. So I asked a few people in the medical affairs space, would it be useful to have a database of uh a monthly uh emails spreadsheet of all of the events or topics that were coming up that month?
SPEAKER_01And you could then pick and choose. And the overwhelming response was yes. So I did the spreadsheet, then some wise guy uh said, Oh, we you know it would be really good if you made it like Netflix. So uh I checked the budgets for the uh for the other companies that I'm running and uh found enough to put a bit aside to build what we do refer to as the Netflix for medical affairs professionals. We call it mymedicalaffairs.com. And uh yeah, so far the uh the the response and reception's been really um really kind and and pleasing, and I think we found a nice little niche in the industry to support our customers uh to fill the need that that I sorely needed at the at the time and and learn more about uh what's available within the space because there's one really amazing thing about the medical affairs community that that differs a little bit from commercial, and that is the willingness to exchange uh um ideas on best practice.
SPEAKER_01The uh there's not so many sensitivities around sharing uh or or a d focus on sharing uh commercially sensitive.
SPEAKER_00It's less competitive, right?
SPEAKER_01Yeah, it's sharing information that's gonna better create a better model holistically for the industry to better service clinicians or healthcare professionals in general, and of course, leading on to patients. So, because of that, it's just it's it's a really great community type feel. And I don't want to um cast any negativity on on commercial because that's my my background and my my first love, as it were. But uh yeah, so the industry is just brimming with amazing content coming out at the at the moment right now. I think it's a lends a great opportunity to move forward uh and and really uh recognize some some meaningful progress in the short to medium term.
SPEAKER_00Yeah, and it's it's so interesting hearing you say that because my medical affairs I really like. Um, and it's it's nice because it feels like a very friendly way to uh access and stay current on what's happening. And quite honestly, that was a large part of what was behind my thinking in launching this podcast, was very similar. It's like, hey, I wanted to similarly get closer connected to my clients, upskill, upskill my language, understand where they're excited, what their concerns are.
SPEAKER_00And I did it by getting directly involved in the conversation, but I think my medical affairs, um which is this is not a sponsored thing or anything, I just really like it. And I think it's I think it's great. So I'm glad I'm glad that you did it and uh found your budget.
SPEAKER_01Yeah, I mean it is you did. I mean, yeah, there's uh there's no commercial reality for me to sponsor anything anyway, because it doesn't make me any money, it's just a nice two for for the industry. I wish I could find a way, but um it's it's better this way.
SPEAKER_00I think no, it's it's it's really good. And then you've also become connected with people uh and I always see your name as somebody who's you know moderating various panels or talk tracks. Um what or other organizations are you connected with?
SPEAKER_01Yeah, it's quite bizarre actually. Somehow, by means of attachment to mymedicalaffairs.com, I've positioned myself to the unfamiliar as a as an expert in the space. So I've gone from somebody who really felt out of his depth to someone who still feels out of his depth in a much bigger uh capacity to expose myself as a pretender. But uh yeah, no, I'm um uh the My Medical Affairs is uh is a media sponsor for most of the the world's biggest um pharmaceutical conferences, including uh the um medical affairs professional society in Nashville next uh next week, which I'll be uh I'll be attending uh and also uh chairing the medical affairs track for Reuters Farmer in um in Europe.
SPEAKER_01It's actually for the second time I've been invited uh back, so obviously I I couldn't have been too bad when nobody nobody nobody cottoned on to the fact I didn't know what I was talking about, I'm not sure.
SPEAKER_00As we were preparing for this podcast, um kind of came up with an interesting idea of crowdsourcing questions. Do you want to talk about that at all?
SPEAKER_01Absolutely. Well, when we uh when we first uh touched base and were thinking about maybe um combining for a uh for for one of your sessions, thought why not make use of this community that we've now got on My Medical Affairs, which is running into the around about 3,000, uh and put it to them instead of us talking about the agenda that suits us. Let's uh maybe step out of our comfort zone a little bit and put it to the crowd. What's most topical and important in the issues of medical affairs that they'd like to see discussed? And uh yeah, so we put the um put the word out and we received a few responses, which we've uh we've gathered a couple here today to talk about, and um hopefully we uh we do the authors of those questions justice.
SPEAKER_01We uh don't profess to be experts, but I think given our background, we hopefully can add uh a little bit of uh insights to uh to the uh to the topics. All right, great. So do you want to read the first one off? Yep, certainly. I've uh got it here in front of me. So first one comes from uh Paul Sims, who uh certainly needs no introduction for for most people in the in the industry. He's the CEO of Impatient Health. Paul asks, what does the future MSL need to be able to do that the current MSL cannot?
SPEAKER_01And of course, how should companies and the MSLs themselves be investing to make this a reality? So a hard-hitting one right off the bat.
SPEAKER_00Yeah, it's it's a really interesting question, and my thought immediately goes to this idea of omnichannel, um, which is something that is often discussed and requested, but I'm not convinced there's even in a widely agreed upon definition um across pharma or even within pharmaceutical companies individually, right? So I think that what's behind that is seeing hey, things were already headed this way, but COVID was this massive accelerant for the need to be really good digitally, and that is widely recognized, and the problem is it's so widely recognized that every pharma company on earth is trying to push more and more digital meaning.
SPEAKER_00The space is getting incredibly crowded and incredibly noisy. So then you have solutions that are popping up that are saying, hey, we can help you parse this data, we can help you get smarter. Um, omnichannel is an extension of that and is different from multi-channel. Like multi-channel is saying, hey, I'm gonna send I'm gonna do five different websites, and I'm gonna do emails, and I'm gonna do texts, and I'm gonna look at open rates. Omni channel is doing all of that, but not focusing on the channel, focusing on the physician in this case for MSLs, right?
SPEAKER_00And so um I think that there's some stuff technologically, there's some stuff structurally that needs to be addressed. There's certainly things from a compliance standpoint, right? Like how much freedom do you want an individual MSL to have, but then it needs to even go back a step further and a step higher at a strategic level at from a company to set clear definitions on what do we see the future of MSL teams being. Um so I'll stop there and see if you're gonna be able to do that.
SPEAKER_01Yeah, no, it's um it's it's an absolute correct point that we're moving forward. It's certainly going to uh be more the omni-channel approach is going to be consolidated even and refined as as we move forward. And I think your um your the something something you just touched on then with the the strat the medical affairs and MSLs being involved strategically in defining the way forward. I think this touches on something that I'm that has really uh resonated a lot with me recently, and that is medical affairs, MSLs and medical affairs teams in in a whole now have a um a greater presence at the table, pharmaceutical table, in terms of strategy and having oversight and input into the development of strategy.
SPEAKER_01So my answer to it to Paul's question takes a different tract in that I think that MSLs, as a starting point, need to really develop a commercial mindset. But I believe that they need to be conscious of the commercial mindset. Um I get a lot of feedback from um from people that do training and communications training in in the medical affairs space, saying that there just seems to be an attitude where medical affairs, they said we know the science, and that's all we need to know, that's what we're here for.
SPEAKER_01And I understand when MSLs first went out, I heard somebody refer to it the other day, kind of like MedInfo on wheels sort of thing. And instead of having to call up, they'd they'd go around and support everybody. But as now the the move, the MSL is a very um uh very an ubiquitously adopted uh module within a company, the uh they're not only providing information, but they're becoming in many instances the sole representative of that company. So the ability to upskill and not only be aware of the commercial realities and what's involved in them as a representative of that company, but also upskilling themselves to have with a commercial mindset helps a number of things.
SPEAKER_01It helps improve communication skills, and again, it's one thing to know the science, but it's another thing to know how to relay it in a way that's relatable to that individual clinician and and being able to understand and address behaviors to build better relationships. I um it's it's it often gets shoved straight into well, that's commercial sort of stuff. But it's a skill set that's in important. I like in in today's um environment where access is not only difficult for reps, it's exceptionally difficult for reps, maybe less so difficult for MSLs, but I understand if if you're a new MSL on territory, or particularly a new SL who doesn't have existing relationships with your key um clinicians, it's very difficult to get through the door and find a way to do that.
SPEAKER_01And that's where some sort of commercial aptitude, ability to think um strategically and and out of the box will help to boost the opportunity to uh convert some of those in um efforts into meetings and then build those relationships that are going to be required to foster the insights that will then feed strategically back to the table in uh at a at a more holistic level in the company. So I guess I've just gone around the world a little bit in my um response, but uh upskilling certainly in the communications and commercial aptitude will be a fairly pivotal component of the of the future MSL.
SPEAKER_00Yeah, and I think that could actually go hand in glove with say it, uh an actual emphasis on omnichannel. Because if you think about it, right, one of the things Med Metaffares does really well, I mean, with your ad boards, right? Any ad boards, they are fantastic communicators, and that starts with understanding. Um, and that's you know, uh an adboard is the most active listening you can imagine.
SPEAKER_00Tracking an HCP's digital behavior could be a very strong kind of passive listening skill if you're understanding that, and if you're able to take insights from that and say, oh, you know, I understand that this particular person, based on a combination of uh conversations and their activities, they're treating an uh underinsured uh population, an impoverished population here in the US. So for them, it's actually not all about MOA, it's not all about efficacy, it's actually about access, right?
SPEAKER_00And if you are a new MSL who's just approaching their territory for the first time, that might be a really important thing to know. And it might help you gain credibility instantly. So I think that, and it also gets back to this idea of like we shouldn't, it's not a digital strategy and an in-person strategy, it's just a strategy, right? And those things need to need to be the same and and make each other better.
SPEAKER_01Yeah, I couldn't agree more. It all feeds into one into each other and ultimately for the benefit of the of the clinician. And uh and that's what it's all all about.
SPEAKER_00Yeah. All right, so question number two, I'll read off and I'll let you go. Um it comes from Michael Stewart. And it's in this in the fast-paced environment, which is medical affairs, many professionals are stretched just to do their job. So there's little time for learning new skills or developing others. Is there a concern that people who aren't learn learning may leave?
SPEAKER_00This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams incidents into the perfect advisory board platform to save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com.
SPEAKER_01Yeah, it's quite a um relevant question in the in the space today with uh medical affairs as uh as we all know is the the the the field is evolving at at a quite a frightening uh pace and uh role new roles being created and new responsibilities being absorbed and that type of thing. So people kind of are scrambling to find their feet and catch up to the catch up to the job descriptions that are changing underneath them. But I do um the question makes me uh it brings back a cartoon I once saw to mind where um a manager asks the managing director or something, what if we do spend all this money upskilling our um our our staff and then they leave?
SPEAKER_01And the response was well, what if we don't spend any money to upskill these um support and they stay? So um, you know, it's quite uh it's quite an astute sort of observation. It but uh it does bring us back to what do the medical affairs teams have time and um you know what are they going to feel neglected if they don't receive it. I think maybe there's during this transitional period there's certainly going to be challenges getting people to to upskill, which is where I think there's it needs to be explored outside service providers who can offer these types of training services that aren't as formal as what we necessarily think of.
SPEAKER_01We we traditionally reflect on training as okay, we're taking a week out, we're all going to this conference centre, and uh we're getting this external agency to come in and talk to us for for a week and that sort of stuff, and then we'll all be set. It doesn't really work like that anymore. It's not the ideal learning environment, anyway, as we all remember. We'd spend too much time socializing at the bar in the evenings anyway, and uh to forget the key lessons. But yeah, there's there's um with micro-learning, with digital platforms all coming in where you can contribute and uh disseminate and understand in your own time throughout the uh day, I think that's the sort of approach that needs to be embraced now.
SPEAKER_01And I I know of several companies working in the life science space from communications to science and uh understanding of deciphering clinical papers and that type of thing, where they do offer these bite-sized, you know, hour-long tops lessons for for companies to uh to embrace. And of course, the beauty of it as a manager, you can track all of these things and see who's engaging with the content and see who isn't, identify the sticky points and that type of thing. So they're really when uh when the medical affairs managers get time and uh the training departments have uh have capacity to explore these solutions, there really is a whole world of opportunity out there to to embrace and even you know um develop something internally of a of a similar nature if they think it's worthwhile.
SPEAKER_00Yeah, it's such a good distinction you made between the you know this carving out a massive block of time and going for more of the on-demand, the micro micro learnings. One thing that's interesting with this question is it sort of implies that maybe at one point there wasn't people weren't stretched so thin, or maybe in the future they won't be again. But if we really stop to think about it, like the if you're a medical director out there, uh as anybody being given the budget to say, hey, take it easy. Yeah, exactly. Just relax, it's enough.
SPEAKER_00No, it's not gonna happen, right? So at one point when I was I was managing a sales team for a tech company and I was I was considering whether to hire this trainer, and it's like, oh, it's not a good time, the end of the quarter is coming up, blah, blah, blah, blah, blah. He's like, John, there's never a good time for training. It's never going to be. You can't, it's it, but it is important, right? If you believe that getting increasing the efficiency of your team and helping people do their job better, then you have to make time. And to your point, it's easier now than it it might have been in the past.
SPEAKER_01Yeah, yeah. No, I think we're in a we're in a good space which not only our roles are evolving, but the service providers and the offerings are evolving, doing their best to keep up, to modify a solution that's going to suit them the modern medical affairs team and that type of thing. So um, if you are out there looking for solutions, it they're only a Google search away.
SPEAKER_00All right, do you want to do the honors on question three?
SPEAKER_01Well, it kind of uh that was uh an inadvertently a segue into the third question relating to Google searches, I guess. It comes from um Julia Walsh, who's the CEO of a company called Brand Medicine International. She's also a published published author on the on the topic. And her question, um, she's actually just broken the mould a little bit here and offered a question and with and given us a multiple choice in terms of answering it, and uh we can we can um justify our answers, I I guess. So the question is Does medical affairs need to consider what happens when questions are exchanged for health advice online as part of their remit?
SPEAKER_01So it's a pretty uh pretty curly one right there. So you're the three options um A No, it's none of Medical Affairs' business what happens when patients or even doctors Google. Okay, so um it's pretty uh pretty short and sharp. Or there's B, perhaps we should be aware of the real-world digital information experience of our stakeholders, but there is nothing we can do about it. So that's that's that. Or C, yes, we uh we medical affairs should be um uh observing this and they have an opportunity to lead the change to clean up the internet for patients to ensure quality use of medicines and also support the delivery of evidence-based content to HCP stakeholders when they seek information about medicines online.
SPEAKER_01So yeah, that's uh um you've got three options there, John. We'll uh we'll see if uh I'll let I'll I'll allow you to go first and we'll see if we align.
SPEAKER_00All right. Well, I mean I would love to say three, but I'm gonna I'm gonna say two and a half or three-ish. Um I'm I'm very much on board with three, except I actually don't believe that medical affairs has a responsibility to clean up the internet as it relates to health misinformation. I just think that's that's too much. I've seen various stats, but at one point I saw a stat that something like 20% of all internet traffic was uh this like erroneous healthcare information.
SPEAKER_00So I wouldn't go I wouldn't go quite that far, but I would file this under um not our fault, but still our problem, uh, because the patients that you're engaged with, the doctors that you're speaking to, or nurse practitioners or other healthcare providers, they're all dealing with this reality of the first thing anybody doing when they get sick or feel something coming on is a Google search, right? And you might get you get what you get. Um, as they say at my kids' school, you get what you get and you feel what you feel.
SPEAKER_00Um but um I do think that it's really important to be informed about what that looks like for your particular space. And then it does seem like there's an opportunity to be that educator that everybody in medical affairs wants to be. And you could this is important information that could actually, although it is not directly tied to you know efficacy of a drug or something like this, it is tied to how your doctors are treating their patients that might end up on your product. So I hope that wasn't a cop-out, but that's that's sort of how I see it.
SPEAKER_01No, I like it. And there are certain realities that we need to put in place that there's only so much that you can do when it comes to the internet, and of course the internet in its evolving state, um, we touched before on Chat GPT, where um we're we're going to be chasing our you know, chasing it before we catch it for chasing for quite some time. But I think this issue is it's kind of it's different in different countries. So obviously in in the United States, you have the opportunity to not promote but educate about different brands online. So somebody gets prescribed um uh Zyprexa, they uh go straight to the Zyprexa website just for a brand I've pulled out of thin air.
SPEAKER_01But um in most other countries in the world, if you get prescribed a drug and the first thing you do is Google it, pharmaceutical companies are are not allowed, you know, at the markets like Australia and the UK and um Germany in particular, they're pharmaceutical companies are not allowed to have anything that brand related in the public domain. And to access content that is about the brand, you need to be a clinician, you need to validate and verify yourself before you can access it. So the majority of time you've got customers or patients Googling, looking for information, the information that's available to them is often from pharmaceutical companies overseas where indications and dosing and types of things may be different, or it could be information written by people who are maybe not qualified to give it.
SPEAKER_01So there is certainly an issue out there in the markets where that information isn't made readily available to them. And whether or not this is a an opportunity for medical affairs teams in these markets to work collectively, I think this is where the opportunity really is. The industry has to come um merge to figure out a way to do that in the countries where where it is an issue. Not so much in the US, but certainly in the markets that I've seen where misinformation is a big deal. The um I think commercially there's never been any sort of desire from companies to want to work together in a unified platform to disseminate information about products.
SPEAKER_01I think medical affairs will look at a little bit differently. They'll be received by regulation, regulatory, maybe a little bit more as as less um of uh of an ulterior motive. Not that the industry does, but we're all aware of the of the cynicism that we that we face as an industry. So uh yeah, I think there is a responsibility, but not uh not one that's actually that that will be deemed failures if we don't address. But I just think medical affairs is is best placed to try and orchestrate some type of way forward and change.
SPEAKER_01I mean, I I have dreams of this utopian kind of hub for pharmaceutical companies, and you as a patient you can go to it, you pick your brand, and you get fed so that all the all the brands can be there. It's a nice depository of information led by pharmaceutical approved content information for patient consumption. But that's a long way off.
SPEAKER_00But uh, if anyone can make it happen, maybe it's benefit. Well, it's interesting, right? Because there's the the internet and then there's the social media internet as as well, where it's there was just a great um article that came out I think yesterday or the day before from the MIT technology review. And what they were talking about was um essentially these drugs being used off label for weight loss. They're the category is GLP1-RA.
SPEAKER_00So uh Govi is one, Ozempik is another. And I think hashtag Ozempic had something like 600 million views on TikTok. And these aren't these are not sponsored, these aren't paid for by the pharmaceutical company, these are like weight loss influencers talking talking about these products.
SPEAKER_02Yeah.
SPEAKER_00Unders, I feel like it is important for a doctor to understand the scale of that because that was that was kind of shocking to me, right? And it's like if you're dealing with a patient, even if it's not a diabetic patient, and they're you know 20 to 35, there's probably a good chance they've seen some of this content or engaged with it in some way.
SPEAKER_01The trust that patients have with their own uh network of of patients is uh immeasurable as well. And it's up there with perhaps even supersedes their relationship with their clinician in in some instances. It's it's very heavily um emotive stuff.
SPEAKER_00Yeah, yeah.
SPEAKER_01Well, fascinating. Anything, uh, anything you'd like to say in close? We could talk about it all day long. Uh, it just reminded me, you know, the power of patient influence. So it I was calling on a doctor once in Cairns, which is in northern uh northern Queensland at the top at the where the Great Barrier Reef is uh is in full play, and uh talking about a medicine that I was detailing and uh talking about an adverse event that uh one of their patients had because their neighbor their neighbor over the fence said, Oh, I've got that particular condition, try one of these. And uh the patient, well, of course, right and it just gets to show the level of trust you have in like that's your next door neighbor, that's one thing, but now people online you feel you automatically have a bond with, so it does create a very interesting playing field and one that uh will continue to provide challenges for medical affairs um in the industry.
SPEAKER_00Well, it's funny, a couple podcasts ago, um I had this gentleman by the name of Chris Cottle on, and he was talking about um I think in Europe or UK, I I actually quite honestly forget the details. They had just um released social media guidance essentially uh for the pharma companies. Of course, over there they can't do the patient stuff, but it's it's it feels very, very challenging for the regulatory agencies to catch up with how fast you know these new networks and and the internet changes.
SPEAKER_00So it does seem like if Metaffairs believes they can make a difference, it would be a great thing to do because it it would almost be impossible for governments to stick to get ahead of this, right? And they're we're just they're just trying to catch up with with their guidance.
SPEAKER_01Yeah, I think we'll be chasing for a little while yet. It reminds me of um the in the Olympics, the the the drug, uh the cheats and the and the testers. The cheats are always ahead of the testers. So you've got to you've got to try and out with them at their own game and beat the technology before and so that you're there when the patients arrive. But uh we might be away there yet.
SPEAKER_00Well, and to give some medical affairs teams credit, um, I've had people that have been interested or I have had had conversations with people who want to get in there and want to have a legitimate voice at the table, and I and have figured out a way to do so in a compliant manner, which is usually, you know, it's not gonna be a dancing TikTok video talking about how awesome the drug is. It might be a talking head pointing to a landing site of uh you know approved, researched back information, but they are making the effort and they are on the channel.
SPEAKER_00So I do feel it's a little bit of if there's a will, there's a way. Um, and just being flexible with what does success look like to even be in the conversation there.
SPEAKER_01Yeah, that's amazing. It's really promising to see those sort of steps being made. And uh, like we touched on the start, if the uh medical affairs team can share the the left their case study or level of success that they have had, I'm sure it'll be uh best practice will filter around and progress will be made.
SPEAKER_00All right, well let's leave it there on that note of optimism. Thank you so much. Thanks, John. It's been a pleasure. Talk soon. This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in teams? And the answer back then was not really.
SPEAKER_00Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own teams instance. It changes teams just enough to check all the boxes for what's needed for great ad boards. And also it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, we're back to the show.
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...